Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

TMS is a well-established therapy for treatment-resistant depression. Large clinical studies show that it significantly reduces symptoms in 60 to 70% of patients, and 25 to 35% achieve remission. Most ...

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible ...

A weeklong, high-intensity version of TMS may work nearly as well as the standard six-week treatment for depression. In a UCLA study, patients who received five sessions a day for five days ...

For the many patients with depression who haven't found relief through medication, transcranial magnetic stimulation (TMS) - ...

Patients are commonly diagnosed with treatment-resistant depression when they do not improve despite receiving two or more pharmacologic treatments for an adequate dose and duration during the same ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has reported its fourth quarter and full-year 2025 financial results, highlighting progress across several clinical programs targeting mental health disorders ...

Gerald sat in his kitchen in Tucson and cried into a bowl of oatmeal the morning after his first psilocybin session — not ...

A forensic psychologist testified that Matthew Schleier’s worsening mental health left him unable to function normally in ...

Researchers from Japan have uncovered direct evidence showing how ketamine exerts its rapid antidepressant effects in ...